T1	Participants 0 90	REVIVE Trial: Retrograde Delivery of Autologous Bone Marrow in Patients With Heart Failure
T2	Participants 143 233	patients with end-stage heart failure and ongoing symptoms despite optimal medical therapy
T3	Participants 300 385	patients with either ischemic heart failure (IHF) or nonischemic heart failure (NIHF)
T4	Participants 422 445	multicenter, open-label
T5	Participants 569 615	Sixty patients were stratified by IHF and NIHF
